Exposure to TNF Inhibitors is Rare at MOGAD Diagnosis

TNF inhibitors and Heart Failure

John J. Cush, Kathryn H. Dao, Catalina Orozco Chronic systemic inflammation yields a notable and proportional risk for myocardial infarction, coronary artery disease, heart failure and cardiovascular (CV) death. The role of tumor necrosis factor (TNF) in the pathogenesis of cardiovascular events and congestive heart failure (CHF) in rheumatoid arthritis (RA) has been well documented (1-4). TNFα...

Immediate Exposure to TNF-α Activates Dendritic Cells Derived from Non-Purified Cord Blood Mononuclear Cells

Background: Tumor necrosis factor alpha (TNF-α) is a primary mediator of immune regulation and might be required in the early stages of DC development from CD34+ cells. However, details of optimal timing of exposure to TNF-α in DC development process in monocytes or non-purified hematopoitic cells are still lacking and clear benefits of this approach to the development of DCs remain to be valid...

Spinal Delivery of p38: TNF-alpha Inhibitors

Cécile Viboud, Mark A. Miller, Bryan T. Grenfell, Ottar N. Bjørnstad, Lone Simonsen While air travel contributes to the spread of infl uenza epidemics, the magnitude of impact is not clear compared to other factors—a crucial issue when considering a fl ight ban in the context of pandemic planning. Recent modeling efforts simulating the spread of pandemic infl uenza have concluded that such an i...

Mycobacterial Infections Associated with TNF-α Inhibitors

TNF-α inhibitors: are they carcinogenic?

Biologic therapy has increasingly been used in the treatment of chronic diseases. Tumor necrosis factor (TNF) is a cytokine implicated in the pathogenesis of rheumatoid arthritis and inflammatory bowel disease. Anti-TNF therapy is being used in the treatment of these conditions. Since the introduction of anti-TNF agents, there have been many case reports of development of malignancy after the i...